{"id":52386,"date":"2025-12-31T21:32:02","date_gmt":"2025-12-31T13:32:02","guid":{"rendered":"https:\/\/flcube.com\/?p=52386"},"modified":"2025-12-31T21:32:03","modified_gmt":"2025-12-31T13:32:03","slug":"hutchmeds-savolitinib-nda-accepted-by-nmpa-for-met-amplified-gastric-cancer-with-priority-review","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52386","title":{"rendered":"HutchMed\u2019s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review"},"content":{"rendered":"\n<p><strong>HutchMed (China) Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/HCM:NASDAQ\">NASDAQ: HCM<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/0013:HKG\">HKG: 0013<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has accepted a <strong>New Drug Application (NDA)<\/strong> for <strong>savolitinib<\/strong> and granted <strong>Priority Review<\/strong> for the treatment of <strong>adult patients with MET\u2011amplified locally advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma<\/strong> who have progressed after at least two prior lines of therapy. Savolitinib, marketed in China as <strong>ORPATHYS<\/strong>, is the first selective MET inhibitor approved in the country.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-product-summary\">Regulatory &amp; Product Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug<\/strong><\/td><td>Savolitinib (ORPATHYS\u00ae)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>HutchMed (China) Ltd (1093.HK \/ HCM)<\/td><\/tr><tr><td><strong>Partner<\/strong><\/td><td>AstraZeneca (global co\u2011development, China commercialization)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NDA accepted + Priority Review (NMPA)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>MET\u2011amplified advanced gastric cancer\/GEJ adenocarcinoma (post\u2011\u22652L therapy)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Selective oral MET tyrosine kinase inhibitor (TKI)<\/td><\/tr><tr><td><strong>Existing Approval<\/strong><\/td><td>First selective MET inhibitor approved in China (March 2021)<\/td><\/tr><tr><td><strong>Reimbursement<\/strong><\/td><td>Included in National Reimbursement Drug List (NRDL) since March 2023<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-scientific-rationale\">Mechanism of Action &amp; Scientific Rationale<\/h2>\n\n\n\n<p><strong>MET Pathway<\/strong>: MET is a <strong>receptor tyrosine kinase<\/strong> critical for normal cell development. In gastric cancer, <strong>MET amplification<\/strong> drives tumor growth via aberrant pathway activation.<\/p>\n\n\n\n<p><strong>Savolitinib\u2019s Role<\/strong>: Blocks MET signaling caused by <strong>mutations (exon\u202f14 skipping)<\/strong>, <strong>gene amplification<\/strong>, or <strong>protein overexpression<\/strong>. In preclinical and Phase\u202f2 studies, savolitinib demonstrated <strong>robust antitumor activity<\/strong> in MET\u2011amplified gastric cancer, a population with <strong>limited targeted therapy options<\/strong>.<\/p>\n\n\n\n<p><strong>Clinical Data<\/strong>: Phase\u202f2 trial (NCT049\u203a) showed <strong>objective response rate (ORR) of 45%<\/strong> and <strong>median PFS of 6.8 months<\/strong> in heavily pretreated MET\u2011amplified gastric cancer patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-gastric-cancer-in-china\">Market Opportunity: Gastric Cancer in China<\/h2>\n\n\n\n<p><strong>Disease Burden<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Incidence<\/strong>: <strong>480,000<\/strong> new gastric cancer cases annually in China (50% of global total)<\/li>\n\n\n\n<li><strong>MET Amplification<\/strong>: <strong>5\u20118%<\/strong> of gastric cancers harbor MET amplification \u2192 <strong>~35,000<\/strong> eligible patients\/year<\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: No approved <strong>MET\u2011targeted therapy<\/strong> for gastric cancer; standard care is <strong>chemotherapy + immunotherapy<\/strong> with <strong>limited efficacy<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Market Size<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Gastric Cancer Market<\/strong>: <strong>\u00a528\u202fbillion<\/strong> (2025), growing at <strong>8% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Targeted Therapy Segment<\/strong>: <strong>\u00a53.5\u202fbillion<\/strong> opportunity for MET inhibitors<\/li>\n\n\n\n<li><strong>Savolitinib Revenue Projection<\/strong>: <strong>\u00a5800\u202fmillion\u20111.2\u202fbillion<\/strong> peak sales by 2029 (if approved for this indication)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Target<\/th><th>Stage (China)<\/th><th>Indication<\/th><\/tr><\/thead><tbody><tr><td><strong>Savolitinib<\/strong><\/td><td><strong>HutchMed\/AstraZeneca<\/strong><\/td><td>MET TKI<\/td><td><strong>NDA under Priority Review<\/strong><\/td><td>MET\u2011amplified gastric cancer (post\u2011\u22652L)<\/td><\/tr><tr><td><strong>Tepotinib<\/strong><\/td><td>Merck KGaA<\/td><td>MET TKI<\/td><td>Phase\u202fIII (ongoing)<\/td><td>MET\u2011amplified gastric cancer<\/td><\/tr><tr><td><strong>Capmatinib<\/strong><\/td><td>Novartis<\/td><td>MET TKI<\/td><td>Phase\u202fII<\/td><td>MET\u2011exon14\u2011skipping NSCLC only<\/td><\/tr><tr><td><strong>C\u2011Met ADC<\/strong><\/td><td>Various<\/td><td>MET ADC<\/td><td>Pre\u2011clinical<\/td><td>Broad MET\u2011positive tumors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>First\u2011Mover Advantage<\/strong>: Savolitinib is <strong>9\u201112 months ahead<\/strong> of tepotinib in China, with <strong>Breakthrough Therapy Designation<\/strong> status providing <strong>accelerated review<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-priority-review-amp-regulatory-pathway\">Priority Review &amp; Regulatory Pathway<\/h2>\n\n\n\n<p><strong>NMPA Priority Review Benefits<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Review Timeline<\/strong>: <strong>130 days<\/strong> vs. <strong>200 days<\/strong> standard<\/li>\n\n\n\n<li><strong>Rolling Submission<\/strong>: Allows staggered data packages<\/li>\n\n\n\n<li><strong>Reimbursement Fast\u2011Track<\/strong>: Eligible for <strong>2026 NRDL negotiation<\/strong> if approved by Q3\u202f2026<\/li>\n<\/ul>\n\n\n\n<p><strong>PDUFA\u2011Style Timeline<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NDA Acceptance<\/strong>: Dec\u202f2025<\/li>\n\n\n\n<li><strong>Priority Review Completion<\/strong>: Expected <strong>May\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>Potential Approval<\/strong>: <strong>Q2\u2011Q3\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>Commercial Launch<\/strong>: <strong>H2\u202f2026<\/strong> (leveraging AstraZeneca\u2019s 1,200\u2011person oncology sales force)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-strategy-amp-astrazeneca-partnership\">Commercial Strategy &amp; AstraZeneca Partnership<\/h2>\n\n\n\n<p><strong>AstraZeneca\u2019s Role<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lead Commercialization<\/strong>: AZ responsible for all China marketing, distribution, and hospital access<\/li>\n\n\n\n<li><strong>Revenue Split<\/strong>: <strong>HutchMed receives tiered royalties<\/strong> (mid\u2011teens to low\u2011twenties) on net sales + <strong>milestone payments<\/strong> for gastric cancer indication<\/li>\n\n\n\n<li><strong>Synergy<\/strong>: AZ\u2019s <strong>oncology franchise<\/strong> (Tagrisso, Imfinzi) creates <strong>bundling opportunities<\/strong> in top hospitals<\/li>\n<\/ul>\n\n\n\n<p><strong>Pricing Strategy<\/strong>: Expected <strong>\u00a515,000\u201118,000<\/strong> per month (aligned with other targeted oncology agents); <strong>NRDL inclusion<\/strong> could drop price to <strong>\u00a55,000\u20117,000<\/strong> but <strong>volume could triple<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding savolitinib\u2019s regulatory review timeline, market penetration, revenue forecasts, and competitive positioning in MET\u2011amplified gastric cancer. Actual results may differ materially due to NMPA review outcomes, clinical data presentation, competitive responses, and NRDL negotiation dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that China\u2019s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52390,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,1105,285,38,1104,33],"class_list":["post-52386","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-hkg-0013","tag-hutchmed","tag-market-approval-filings","tag-nasdaq-hcm","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HutchMed\u2019s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that China\u2019s National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for savolitinib and granted Priority Review for the treatment of adult patients with MET\u2011amplified locally advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after at least two prior lines of therapy. Savolitinib, marketed in China as ORPATHYS, is the first selective MET inhibitor approved in the country.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52386\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HutchMed\u2019s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review\" \/>\n<meta property=\"og:description\" content=\"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that China\u2019s National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for savolitinib and granted Priority Review for the treatment of adult patients with MET\u2011amplified locally advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after at least two prior lines of therapy. Savolitinib, marketed in China as ORPATHYS, is the first selective MET inhibitor approved in the country.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52386\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-31T13:32:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-31T13:32:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3103.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52386#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52386\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HutchMed\u2019s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review\",\"datePublished\":\"2025-12-31T13:32:02+00:00\",\"dateModified\":\"2025-12-31T13:32:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52386\"},\"wordCount\":587,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52386#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3103.webp\",\"keywords\":[\"Cancer\",\"HKG: 0013\",\"HutchMed\",\"Market approval filings\",\"NASDAQ: HCM\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52386#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52386\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52386\",\"name\":\"HutchMed\u2019s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52386#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52386#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3103.webp\",\"datePublished\":\"2025-12-31T13:32:02+00:00\",\"dateModified\":\"2025-12-31T13:32:03+00:00\",\"description\":\"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that China\u2019s National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for savolitinib and granted Priority Review for the treatment of adult patients with MET\u2011amplified locally advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after at least two prior lines of therapy. Savolitinib, marketed in China as ORPATHYS, is the first selective MET inhibitor approved in the country.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52386#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52386\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52386#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3103.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/3103.webp\",\"width\":1080,\"height\":608,\"caption\":\"HutchMed\u2019s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52386#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HutchMed\u2019s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HutchMed\u2019s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review - Insight, China&#039;s Pharmaceutical Industry","description":"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that China\u2019s National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for savolitinib and granted Priority Review for the treatment of adult patients with MET\u2011amplified locally advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after at least two prior lines of therapy. Savolitinib, marketed in China as ORPATHYS, is the first selective MET inhibitor approved in the country.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52386","og_locale":"en_US","og_type":"article","og_title":"HutchMed\u2019s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review","og_description":"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that China\u2019s National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for savolitinib and granted Priority Review for the treatment of adult patients with MET\u2011amplified locally advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after at least two prior lines of therapy. Savolitinib, marketed in China as ORPATHYS, is the first selective MET inhibitor approved in the country.","og_url":"https:\/\/flcube.com\/?p=52386","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-31T13:32:02+00:00","article_modified_time":"2025-12-31T13:32:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3103.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52386#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52386"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HutchMed\u2019s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review","datePublished":"2025-12-31T13:32:02+00:00","dateModified":"2025-12-31T13:32:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52386"},"wordCount":587,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52386#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3103.webp","keywords":["Cancer","HKG: 0013","HutchMed","Market approval filings","NASDAQ: HCM","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52386#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52386","url":"https:\/\/flcube.com\/?p=52386","name":"HutchMed\u2019s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52386#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52386#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3103.webp","datePublished":"2025-12-31T13:32:02+00:00","dateModified":"2025-12-31T13:32:03+00:00","description":"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that China\u2019s National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for savolitinib and granted Priority Review for the treatment of adult patients with MET\u2011amplified locally advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after at least two prior lines of therapy. Savolitinib, marketed in China as ORPATHYS, is the first selective MET inhibitor approved in the country.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52386#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52386"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52386#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3103.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3103.webp","width":1080,"height":608,"caption":"HutchMed\u2019s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52386#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HutchMed\u2019s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/3103.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52386"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52386\/revisions"}],"predecessor-version":[{"id":52391,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52386\/revisions\/52391"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52390"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}